Trade PROCEPT BioRobotics Corporation - PRCT CFD

Trading Conditions

• Spread: 0.19
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 52.2
• Open: 51.96
• 1-Year Change: 45.67%
• Day's Range: 51.15 - 52.48

PROCEPT BioRobotics Corporation Company profile

About Procept Biorobotics Corp

Procept Biorobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). Its AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. It designs Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Procept Biorobotics Corp revenues increased from $7.7M to $34.5M. Net loss increased 13% to $59.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 10% to $5.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.38.